Home LiteratureArticle Details
PMID: 12734353 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 170 ·No. 10 ·2003-05-15 ·Pages 5082-8

Brown GR, Lee EL, Thiele DL

Abstract

Inhibition of TNF/TNFR2 interactions ameliorates intestinal graft-vs-host disease (GVHD) and Th1 cytokine responses induced by transfer of B6 CD4(+) spleen cells into irradiated MHC class II disparate B6.C-H-2(bm12) (bm12) x B6 F(1) recipients. The present studies examined whether these effects of TNF are IL-12 dependent. T cell proliferative responses of B6.129S1-IL-12rb2(tm1Jm) (B6.IL-12R(-/-)) responder spleen cells were found to be comparable to those of control B6 spleen cells. TNF inhibition reduced T cell proliferation and IFN-gamma production in supernatants of MLC using either B6.IL-12R(-/-) or control B6 responder cells. GVHD induced wasting disease in recipients of B6.IL-12R(-/-) CD4(+) spleen cells that received a TNF inhibitor-encoding adenovirus (5.4 +/- 6.5% weight loss (n = 7)) was significantly reduced compared with levels of weight loss observed in recipients that had received a control adenovirus (25.7 +/- 12.2% weight loss (n = 11), p = 0.001). Furthermore, TNF inhibition was associated with a reduction in colonic GVHD scores (p = 0.039) and in the percentage of the splenic CD4(+) T cells that expressed IFN-gamma (16 vs 6%). These findings indicate that TNF promotes CD4(+) T cell alloproliferation, IFN-gamma responses, and intestinal GVHD by IL-12-independent mechanisms.

MeSH Terms
Animals Bone Marrow Transplantation/immunology,pathology CD4-Positive T-Lymphocytes/immunology,metabolism,transplantation Cells, Cultured Colonic Diseases/genetics,immunology,pathology,prevention & control Down-Regulation/genetics,immunology Female Graft vs Host Disease/genetics,immunology,pathology,prevention & control Histocompatibility Antigens Class II/genetics Humans Immunoglobulin Heavy Chains/genetics,pharmacology Interferon-gamma/antagonists & inhibitors,biosynthesis Interleukin-12/physiology Interleukin-18/biosynthesis Lymphocyte Activation/genetics Lymphocyte Culture Test, Mixed/methods Male Mice Mice, Inbred C57BL Mice, Mutant Strains Receptors, Interleukin/deficiency,genetics,physiology Receptors, Interleukin-12 Receptors, Tumor Necrosis Factor/genetics,physiology Recombinant Fusion Proteins/pharmacology Spleen/cytology,immunology,metabolism Tumor Necrosis Factor-alpha/antagonists & inhibitors,physiology
Chemicals
Histocompatibility Antigens Class II Immunoglobulin Heavy Chains Interleukin-18 Receptors, Interleukin Receptors, Interleukin-12 Receptors, Tumor Necrosis Factor Recombinant Fusion Proteins Tumor Necrosis Factor-alpha Interleukin-12 Interferon-gamma
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Brown Geri R
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, and Dallas Veterans Affairs Medical Center, Dallas, TX, USA. gbrow1@mednet.swmed.edu
Lee Edward L
Thiele Dwain L
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2003-05-15
Pages
5082-8
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NIAID NIH HHS · R01 AI-24639 · United States
NHLBI NIH HHS · R01-HL69006-01A1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com